Press Room

Our President and CEO Prahlad Singh recently joined Jim Cramer on CNBC’s Mad Money to describe how agility and innovation continue to fuel PerkinElmer's transformation. In this interview, Prahlad talked about the Company's recent acquisitions and future opportunities in the Life Sciences and Diagnostics sectors.

Mycotoxins pose many challenges for feed and grain suppliers at every stage from harvest to final production. Mark MacBeath, Food Safety Product leader, and Wes Shadow, Global Market manager of Grain, outline the best technologies to aid mycotoxin monitoring and detection.

Can gene editing technology help transition cell-based therapies to solid tumors? Jonathan Frampton, a Corporate Development Partner on our Horizon Discovery team, looks at the potential evolution of this currently costly approach into mainstream treatment of cancer patients through the application of base editing.

E. coli O157 testing has gained more attention from food producers and processors as the demand grows rapidly. Nevin Perera, Research and Development Manager at PerkinElmer, shares his insights about the steps to take to ensure safe and efficient E. coli testing.

Standardization and validation are foundations in the selection of appropriate technology, methods, reagents and consumables. Anis H Khimani, Senior Strategy and Market Segment Leader at PerkinElmer Life Sciences, discusses how to orchestrate these factors towards a holistic outcome.

Arvind Kothandaraman, general manager of specialty diagnostics at PerkinElmer, talks about the COVID-19 passport concept and how it can be implemented to ensure safe return of in-person trade shows as the world reopens.

One takeaway from COVID-19 is that understanding the mechanisms of viral evolution can help track variants in real time. Arvind Kothandaraman, our general manager of specialty diagnostics, explains how new and emerging technologies have enabled scientists and research to identify and monitor SARS-CoV-2 mutations.

Anis H. Khimani, senior strategy and product portfolio leader for Life Sciences at PerkinElmer, talks about the innovations and challenges in advancing capabilities for protein analytics to ensure the rapid development of safe and effective biotherapeutics.

Automation has helped many labs keep pace with new and increasing demands brought on by COVID-19. In this article, our Global Director of Automated Solutions Carola Schmidt shares advice on how to setup new technology initiatives for success.

Next-generation sequencing (NGS) plays a vital role in COVID-19 surveillance. Our General Manager of NGS Michelle Fraser shares her thoughts on the latest advances in NGS technology and the global effort to track the virus and its variants.

As the demand for faster separations, better peak resolution and lower detection limits increases, more food, pharma and industrial labs are moving from high performance liquid chromatography (HPLC) to ultra-high-performance liquid chromatography (UHPLC). Jackie Trudell, Portfolio Marketing Manager Chromatography and Mass Spectrometry, discusses the benefits and key considerations in making the transition smoothly.

Cell painting allows new strategies for high-content screening (HCS) practitioners to identify new drug candidates and study mechanisms of action by taking advantage of both cellular imaging and machine learning. Alexander Schreiner, high content screening applications leader, and Martin Daffertshofer, high content screening software product manager from PerkinElmer, discuss how cell painting is helping drug discovery and the current technical limitations and challenges.

Jonathan Frampton, a Corporate Development Partner on our Horizon Discovery team talks about how base editing differs from traditional genome editing tools and the exciting advances it could help help bring about, especially in cell-based therapy discovery.

EUROIMMUN announced the SARS-CoV-2 NeutraLISA assay, a surrogate neutralization test for detecting neutralizing antibodies against SARS-CoV-2. This assay is now CE marked in over 30 countries.

Lab automation is increasingly critical for typical discovery and basic life science workflows. PerkinElmer’s executive director for science and technology David Gosalvez walks us through the key challenge for labs to adapt to modern, efficient systems that maximize the potential of instruments, time, and people.

As a new addition to the CRISPR portfolio, the CRISPR interference (CRISPRi) from Horizon Discovery, a PerkinElmer company, will enable researchers to repress genes in almost all cell lines, over any length of time and at any scale from single gene readouts to high-throughput studies.

EUROIMMUN, a PerkinElmer company, has partnered with biotechnology company Oncgnostics to jointly distribute the cervical cancer test that predicts the individual cancer risk of patients.

In part one of a two part microplastics series, Kathleen A. Young, Environmental Market Leader at PerkinElmer, shares her thoughts on how PPE has increasingly impacted our environment and the importance of standardization in detecting microplastics.

PerkinElmer launched its ONE Pesticide420^™ CRM Reagent and Consumable Kit to support pesticide and mycotoxin testing in cannabis and hemp. The new kits free lab technicians from complex preparations and create a simpler workflow path to streamline a lab’s supplier mix.

PerkinElmer announced its Signals informatics platform will integrate with software from Insightful Science to expand on existing capabilities in the biologics drug discovery space, which will reduce research cycle times and accelerate biologics and vaccine development.

To develop new food products and approaches, analytical tools can be used on three crucial stages in monitoring. Wes Shadow, Grain Global Market Manager at PerkinElmer, shares his thoughts around analytical tools and the outlook of food testing.

EUROIMMUN, PerkinElmer’s subsidiary, announced the EUROPattern Microscope Live (EPML) compact immunofluorescence microscope, which is compatible with EUROLabOffice 4.0 (ELO 4.0) software for modern diagnostics.

The latest RUO solutions, PKamp^™ VariantDetect^™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX^® Variant-Seq^™ SARS-CoV-2 Kit, extends PerkinElmer’s testing portfolio to known and unknown variants.

Prahlad Singh, President and CEO of PerkinElmer, sat down with This Week in Business on NECN to talk about the Company’s COVID-19 RT-PCR and antigen tests, and how he perceives the COVID-19 testing landscape to be as vaccines roll out.

To commemorate International Women’s Day, Nicky Xu, General Manager of Diagnostics at PerkinElmer Greater China, shared how she led the development of the COVID-19 PCR test and organized national donations as a female leader.

Masoud Toloue, Senior Vice President of PerkinElmer Diagnostics, talked with 7News in Boston about PerkinElmer’s antigen test that detects SARS-CoV-2 nucleocapsid antigen in under 15 minutes. The test is expected to play an important role in point-of-care testing located at healthcare centers, travel hubs, businesses and schools.

Horizon Discovery, a PerkinElmer company, was licensed by Rutgers University for the modular base editing system that uses RNA aptamers to position DNA modifying enzymes at genome targets. This uses a pin-point system and can enhance the therapeutic potential of genome editing.

Next-generation sequencing (NGS) is used to detect underlying molecular mechanisms and variants in multiple genes to achieve targeted treatment for cancer patients. Keith Cannon, Director of Commercial Product Management and Prabha Nagarajan, Senior Research Scientist at Horizon, a PerkinElmer company, highlight the importance and prospect of NGS initiatives.

As an addition to the PhenoVue cellular imaging reagent portfolio, PerkinElmer’s first cell painting kit completes the suite of high-content screening products and expert services to build more streamlined workflows.

Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, discusses how the emerging genetic variants of SARS-Cov-2 can impact false negative rates and the characteristics RT-PCR assays need to remain accurate.

John Rontree, Portfolio Director and Leader of Mass Spectrometry and Anis H. Khimani, senior strategy and market life sciences segment leader in life sciences at PerkinElmer share their thoughts on quantitation, automation and innovative assays in proteomics as an approach to understanding their role in complex biological systems, supporting high-throughput PCR testing environments and helping drive innovative therapeutics development for COVID-19.

Since their discovery last year, coronavirus neutralizing antibodies have been touted as possible treatments and diagnostic targets. Anis H. Khimani, Senior Strategy and Market Segment Leader at PerkinElmer and Kai Fechner, Director of International Sales and Marketing at EUROIMMUN (a PerkinElmer company), talk about what defines an ideal NAb assay.

While most Escherichia coli strains are harmless, some can cause intestinal illness in groups under higher risk. PerkinElmer’s newly launched Solus One O157 Pathogen Detection Assay provides a highly sensitive, cost effective system with an industry-leading result sample volume.

PerkinElmer announced new additions to the existing GPCR portfolio including an industry’s first GPCR TR-FRET binding assay, along with Beta-Arrestin kits and more.

A new report by PerkinElmer and MIT Technology Review Insights focuses on how leading pharma and chemical companies use AI, quantum computing and other digital technologies to innovate scientific research and elevate R&D performance.

As one of the world’s largest suppliers of laboratory and diagnostic reagents and equipment, PerkinElmer was in prime position to respond to COVID-19. As the pandemic took hold, Iswariya Venkataraman, scientific affairs manager at EUROIMMUN US, a PerkinElmer subsidiary, shares how the Company developed its now-established qualitative test to assist vaccine developers in understanding if their products elicited antibody responses, and how strong those responses were.

Dr. Sanjay Garg, Operations of Sanofi Pasteur and our own Dr. Anis H. Khimani discuss how the COVID-19-driven innovation and collaboration cycles are changing vaccine development forever.

EUROIMMUN, a PerkinElmer company, launched a Research Use Only, SARS-CoV-2 Interferon Gamma Release Assay (IGRA) to determine the activity of T-cells reactive to SARS-CoV-2.

PerkinElmer New Coronavirus Nucleic Acid Detection Kit that originally obtained FDA EUA in the spring of 2020 and is also approved for sample pooling, is now greenlighted by the FDA to test asymptomatic individuals.

Despite the hardship, silver linings can be found amidst the pandemic. Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, shares takeaways for diagnostic labs to help prevent pandemics of this magnitude in the future.

Through the acquisition of Oxford Immunotec, a leading company specialized in diagnosing infection with tuberculosis, PerkinElmer will grow its portfolio of advanced infectious disease testing solutions to include tuberculosis detection to better serve customers around the world.

Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, talks about trends and predictions including additional forecasts for cross-biotech collaboration and the significance of digital technologies.

Dr. Kaveh Kahen, Senior Director and General Manager of Mass Spectrometry at PerkinElmer, highlights technical challenges in cannabis testing and how they can help labs in this growing industry.

Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, shares his thoughts on how COVID-19 will continue to transform modern laboratories in 2021 and beyond.

EUROIMMUN’s Antigen ELISA is a laboratory test, able to be applied in semi-quantitative automatable detection of the SARS-CoV-2 nucleocapsid protein on a large scale.

Carterra, with the expertise in label-free high throughput antibody screening and characterization, announced that they have closed on a round of equity financing led by PerkinElmer.

The CE-marked EURORealTime SARS-CoV-2/Influenza A/B is capable of differentiating the genetic material from SARS-CoV-2, influenza virus type A and influenza virus type B.

The Management Top 250 ranking measures corporate effectiveness by examining performance in five areas: customer satisfaction, employee engagement and development, innovation, social responsibility and financial strength.

PerkinElmer has announced the MaxSignal^™ HTS Total Aflatoxins and DON ELISA Kits featuring automated and easy-to-use mycotoxin testing workflows. This can process up to 192 samples in less than 90 minutes.

This article takes a look back on the evolution of PerkinElmer’s ICP-MS innovations for environmental testing over the past three decades up through the new NexION 5000.

As the second Lighthouse Lab brought online by PerkinElmer on behalf of the DHSC, the Charnwood Lighthouse Lab will increase its daily testing capacity to 50,000 by early 2021.

Our Head of Food, Greg Sears, talks with New Food about trends in food testing and quality, as well as how PerkinElmer’s solutions can help customers meet food and cannabis regulations.

PerkinElmer has launched the newest ChemOffice+ Cloud application for chemistry communication workflows. This offering shifts the inefficient procedures to a new, intuitive cross-document search.

PerkinElmer hosted an exhibit at the Chinese International Import Expo (CIIE) where industry leaders could get an in-person look at our technologies including explorer™ workstations for SARS-CoV-2 testing.

EUROIMMUN, a PerkinElmer company, has launched the new ELISA assay to quantify IgG antibodies against the SARS-CoV-2 S1 antigen.

PerkinElmer has agreed to acquire Horizon Discovery, a company based in the UK that offers gene editing and gene modulation tools, to expand the portfolio of automated Life Sciences and Applied Genomics.

Carola Schmidt, Global Director of Automated Solutions at PerkinElmer, shared her insight about biobanking and how to ensure the integrity and security to standardize the procedure and implement best practices.

Innovative private-public partnership with PerkinElmer will soon allow California to process an additional 150,000 COVID-19 tests a day.

PerkinElmer’s COVID-19 Nucleic Acid Detection Kit is certified for sample pooling to allow a greater number of individuals to be tested without increasing resources.

With the flu season approaching, PerkinElmer has received CE-IVD for the PKamp Respiratory SARS-CoV-2 RT-PCR Panel that simultaneously tests COVID-19, the flu and RSV with only one sample.

PerkinElmer JANUS G3 automated liquid handlers and chemagic 360 closed loop extraction unit have helped Synergy Diagnostic Laboratory in delivering COVID-19 tests to increase the capacity to more than 1,000 tests per shift.

James Coffin, President and Chief Operating Officer, Sema4, talks about how PerkinElmer is providing best-in-class, highly accurate PCR tests (7:40 mark).

The National Center for Advancing Translational Sciences (NCATS) at National Institutes of Health (NIH) is using PerkinElmer’s AlphaLISA no-wash immunoassay to conduct drug compound screening as part of the search for drug repurposing candidates for COVID-19.

PerkinElmer supports BioMarin, a biopharmaceutical firm, for their sponsored testing program in Mexico to identify Batten disease and mucopolysaccharidosis (MPS) disorders.

PerkinElmer launched the industry’s first fully-automated liquid handling sample preparation and LC/MS/MS analysis workflow to detect pesticide residue in cannabis and hemp flower samples.

PerkinElmer helps ramp up testing at “Lighthouse Lab” for Public Health Wales. This aims to expand the capacity to 20,000 tests per day by the end of October.

Adding to the entire newborn screening solutions, PerkinElmer EONIS newborn screening assay simultaneously tests for SMA, SCID and ELA.

Gary Grecsek, Vice President/General Manager of Global OneSource Enterprise Laboratory Services and Tony Pezzolo, Product Manager of Validation, discuss how labs can stay in the know and ahead of the curve on compliance and data integrity challenges with the help of an external, expert compliance team.

Listeria carries a 20 – 30% mortality rate for those in high-risk categories so vigilant testing is important. The PerkinElmer Solus Listeria monocytogenes ELISA Assay tests both food and environmental samples and has been certified by the AOAC.

The FDA released comparative performance data for 58 COVID-19 test manufacturers. PerkinElmer’s detection kit that uses nasopharyngeal swabs in viral transport media topped the list.

Madhuri Hegde, Vice President and Chief Scientific Officer at PerkinElmer Genomics, shared how recent advancements in genomic sequencing technologies are enabling simultaneous rapid analysis for large amounts of genetic information, making it easier and faster to apply these learnings to clinical care.

Stefan Tordenmalm, Market Manager of Processed Food at PerkinElmer, highlights the most common types of food fraud reported by customers and how analytical chemistry helps to ensure food safety and quality.

Iswariya Venkataraman, Scientific Affairs Lead at EUROIMMUN, helped us demystify the differences between the S and N proteins, whose presence indicates the immune response against COVID-19.

Though person-to-person transmission is the primary way of spreading COVID-19, environmental surfaces should also not be neglected. PerkinElmer’s environmental testing kits help detect the virus on surfaces such as plastic, ceramic, or stainless steel.

With COVID-19 continuing to spread and flu season on the way, methanol recalls in hand sanitizers are unwelcomed news. Helping to ensure the safety of these high-demand products, PerkinElmer launched the enhanced Hand Sanitizer Analyzer providing methanol pass/fail results in 30 seconds starting at 300 ppm.

PerkinElmer CEO Prahlad Singh joined Jim Cramer on CNBC’s Mad Money to discuss the how the company’s unique, comprehensive turnkey solutions help in the fight against COVID-19.

The new series of explorer^™ workstations for COVID-19 testing can prepare and run up to 10,000 COVID-19 tests daily. These modular and scalable workstations will increase testing capacity for quicker results.

Sonoma County aims to triple volume of coronavirus test processing with new technologyRachel Rees, director of the public health lab in Sonoma County, California, envisions the lab conducting 900 to 1,200 virus tests per day with PerkinElmer’s technology.

Arvind Kothandaraman, General Manager of Specialty Diagnostics at PerkinElmer, shares seven key factors that organizations should take into consideration when choosing a new COVID-19 testing workflow.

PerkinElmer is dedicated to providing labs with LC-MS software interface and analytical management platforms that are easy to use. Prof. Antonio D’Avolio at the University of Turin talks about how this technology is used to quantify remdesivir, the potential cure for COVID-19.

As global scientists work tirelessly to discover therapeutics and vaccines for COVID-19, there’s massive amounts of existing data that can be invaluable. PerkinElmer has introduced open COVID-19 Data Dashboards to help scientists easily access, analyze and gain insights from data sources.

With the harvest season approaching, PerkinElmer is launching the AuroFlow^® AQ Mycotoxin Platform to screen grain including corn and wheat. This new solution includes strip tests for various of mycotoxin contaminations.

Equipped with a modern user interface and simplified data connectivity, PerkinElmer’s Perten Glutomatic® 2000 System is designed to operate within automated process workflows.

In the part two of the Analytical Cannabis series, Toby Astill from PerkinElmer shared thoughts on topics like adulterant, stability and potency in regard to analyzing cannabis-infused products.

HCS is a powerful tool to help fight viral foes like COVID-19, Ebola, MERS and Zika. Dr. Karin Bottcher talks about how high content screening (HCS) has been used globally to help with drug discovery for repurposing existing drug candidates and creating new therapeutics and vaccines.

Compared with 2D cultures, more complex cultures that use primary cells and multiple cell types in three dimensions provide more physiologically-relevant data for use in target validation.

“FemTech” is a technology that addresses a variety of women’s health issues and according to Karen Madden, Ph.D., Vice President of Technology and Innovation at PerkinElmer, it is gaining more attention. She also shared insights into the Company's Vanadis non-invasive prenatal testing (NIPT) solutions.

Karen Madden, Ph.D., Vice President of Technology and Innovation at PerkinElmer, spoke with The Boston Globe to talk about the current trend and outlook of precision medicine.

With viral tests manufactured by PerkinElmer, Sema4, a Stamford-headquartered firm, has expanded its capacity to run about 15,000 COVID-19 tests per day.

In the first half of the Analytical Cannabis series, our expert Toby Astill discussed the product development and manufacturing of cannabis-based beverages.

PerkinElmer partners with Public Health Wales (PHW) to achieve the Welsh Government’s “Test, Trace, Protect” strategy by providing advanced extraction equipment and testing kits that meet the UK’s ongoing requirements.

With the new EURORealTime SARS-CoV-2 assay, PerkinElmer expands its COVID-19 comprehensive testing portfolio to three FDA EUA solutions.

PerkinElmer has announced the addition of the DELFIA Xpress sFlt-1 kit to its CE-IVD pre-eclampsia product offering to aid in diagnosis in the second and third trimesters of pregnancy.

eXXpedition the all-female microplastics research vessel has returned to dry land due to COVID-19 but continues gaining scientific insights using our FT-IR technology.

PerkinElmer LactoScope FT-B instrument offers rapid and accurate component testing and adulterant screening for dairy products. This instrument can be paired with other PerkinElmer platforms to achieve exhaustive performance.

Amidst COVID-19, PerkinElmer is ready to support our global customers with a wide range of solutions, including detection, workflow and research.

EUROIMMUN Anti-SARS-CoV-2 ELISA testing kits are helping Beaumont Health as part of its research study demystify COVID-19 as the research expands to wider patient groups.

EUROIMMUN provides LabCorp with dried blood spot antibody tests to screen employers as their return-to-work plans.

PerkinElmer Solus One Salmonella, an assay that offers solutions to analyze select foods and delivers results within one day, obtained OMA from AOAC INTERNATIONAL, which is considered the highest level of AOAC certification.

After CE marked in Europe, PerkinElmer’s Anti-SARS-CoV-2 ELISA serological test receives Emergency Use Authorization (EUA) from the FDA.

PerkinElmer’s MaxSignalTM HTS Nitrofurans and Chloramphenicol ELISA Kits offer same-day testing for all five targeted antibiotic residues in farmed shrimp with high accuracy.

Stefan Tordenmalm, Market Manager of Processed Food at PerkinElmer, shares his thoughts about the adulteration of olive oil, which is at high risk for food fraud. To ensure its quality, rapid testing techniques like infrared (IR) and UV-visible spectroscopy (UV-Vis) are crucial in protecting consumers./p>

PerkinElmer’s record for positive social and environmental impact is recognized in story on company’s efforts to expand COVID-19 testing in Texas.

Tailored for pharmaceutical, semiconductor, biomonitoring, food, materials and academia labs, PerkinElmer’s new analysis and automation solutions are designed to help streamline workflows, sharpen insights and meet regulations.

To answer the need for wider COVID-19 testing in the US, EUROIMMUN, a PerkinElmer company, collaborates with Quest Diagnostics to detect immunoglobulin class G (IgG) antibodies. Quest is expected to boost testing to 150,000 a day by early May.

PerkinElmer EUROLabWorkstations and EUROIMMUN Anti-SARS-CoV-2 ELISA testing kits designed to help Beaumont Health gain knowledge about disease transmission and whether COVID-19 antibodies offer protection after infection.

PerkinElmer’s instruments contribute to an antibody study at Beaumont Health, which could potentially identify those with immunity against COVID-19.

Alan Fletcher, vice president and GM, life sciences, shares insights about leveraging the potential of existing drugs to combat COVID-19.

As part of the donation from researchers at Augusta University and Georgia Tech, PerkinElmer’s products help with COVID-19 testing at the GEM lab of Medical College of Georgia.

PerkinElmer’s RT-PCR test assists in screening for COVID-19 at the Clinical and Translational Research Center, University at Buffalo. This effort helps combat COVID-19 in Erie County, NY.

PerkinElmer’s automated lab solutions support Rutgers' RUCDR Infinite Biologics, handling 10,000 nucleic acid extractions per day.

To support the diagnostics of COVID-19, the Anti-SARS-CoV-2 ELISAs for immunoglobulin classes A and G from EUROIMMUN, a PerkinElmer company, is now CE marked in Europe.

PerkinElmer receives Emergency Use Authorization (EUA) from the FDA for the PT-PCR test for detection of COVID-19.

Dr. Stan Naides, the Director of Scientific Affairs at EUROIMMUN, a PerkinElmer company, shares his perspective on COVID-19, its progression and impact on laboratories and their personnel.

In this interview, Petra Furu, the General Manager of Reproductive Health at PerkinElmer, talks about the recently approved DMD screening kit and the promise of non-invasive testings.

Statistics show that women in China are more likely to be in senior leadership roles than many other Asian countries. Here Ms. Ye (Nicky) Xu, General Manager of Diagnostics at PerkinElmer Greater China shares her journey and some career, business and personal growth tips to help inspire the world’s women in science and healthcare.

PerkinElmer’s VICTOR EnLite Instrument and EnLite Neonatal TREC Kit will be available as part of a Severe Combined Immunodeficiency (SCID) evaluation program in collaboration with Public Health England.

When added with LPC 500^™ Liquid Particle Counter, PerkinElmer’s Avio^® 500 ICP-OES can analyze oils or lubricants for both wear metals and particles in one run. This costs less than 1 mL of sample and takes 45 seconds to provide accurate and stable results.

PerkinElmer launches top technologies at the Society for Laboratory Automation and Screening (SLAS) in San Diego. Highlighted products include JANUS^® G3 Blood iQ^™ Workstation, Sciclone^® G3 NGSx HT Workstation as well as Opera Phenix^® Plus High Content Screening System.

To ensure the safety of medicines, PerkinElmer offers pharma companies a comprehensive solution to detect N-nitrosodimethylamine (NDMA) impurity in ranitidine.

PerkinElmer’s liquid handling workstations facilitate sample tracking by incorporating automated barcode scanning into every step of sample processing.

Lead scientist of the eXXpedition research boat Dr. Winnie Courtene-Jones shares how the portable and powerful Spectrum Two FT/IR Spectrometer is being used on board to test for microplastics in our oceans.

As an AI-driven technology solution provider, PerkinElmer is enhancing researchers’ ability to analyze massive amounts of data in a timely fashion.

Together with PerkinElmer, New York State has screened the first infant for Duchenne as part Parent Project Muscular Dystrophy’s (PPMD's) Newborn Screening Pilot.